Author

H. Ryoo

Institutions: Kyungpook National University Hospital, Daegu Fatima Hospital, Daegu Catholic University Medical Center, Keimyung University Dongsan Medical Center, Ulsan University Hospital, Keimyung University, Yeungnam University

Observed institutions: Dongguk University, Kyungpook National University Hospital, Daegu Catholic University, Daegu Fatima Hospital, Daegu Catholic University Medical Center, Keimyung University Dongsan Medical Center, Ulsan University Hospital, Yeungnam University Medical Center, Dongguk University WISE, Keimyung University, Yeungnam University

OpenAlex ID: A5111600896

Fixed dose rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced biliary cancer

2009 · S. Lee, H. Ryoo, et al. · Journal of Clinical Oncology · 3

Prognostic impact of bone marrow involvement for patients with diffuse large B-cell lymphoma in the era of rituximab.

2011 · B. W. Kang, Y. J. Lee, et al. · Journal of Clinical Oncology · 1

Phase II study of fixed-dose-rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced bile duct cancer: Daegu Gyeoungbuk Oncology Group.

2011 · H. Ryoo, S. Bae, et al. · Journal of Clinical Oncology · 1

Phase II study of fixed dose-rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced bile duct cancer: Daegu Gyeoungbuk Oncology Group.

2010 · S. Bae, H. Ryoo, et al. · Journal of Clinical Oncology

3062 The cancer pain survey, 2006 in Daegu, Korea

2009 · H. Song, K. Park, et al. · European Journal of Cancer Supplements

Palliative chemotherapy preferences and factors that influence patient choice in advanced cancer

2006 · M. Kim, K. Lee, et al. · Journal of Clinical Oncology

Works count: 6

Citation count: 5

H-index: 1

I10-index: